SAN FRANCISCO — Eli Lilly mentioned Monday it could purchase a most cancers program from startup Scorpion Therapeutics in a deal value as much as $2.5 billion, because the Indianapolis firm broadens its pipeline.
Lilly has been utilizing its conflict chest of money from gross sales of its weight problems and diabetes medicine to snap up startups like Morphic Therapeutics, DICE Therapeutics, Versanis Bio, and POINT Biopharma.
The brand new deal facilities on a Scorpion drug known as STX-478, which is designed to inhibit mutations within the PI3Kα gene that drive breast, gynecological, and head and neck cancers. As a part of the deal, Lilly is shopping for the privately held Scorpion, however the startup is spinning out a brand new firm that can maintain onto its workers and drug candidates not centered on PI3Kα.
This text is unique to STAT+ subscribers
Unlock this text — plus every day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.